SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)
|
3 Months Ended |
Dec. 31, 2022 |
|---|
| Accounting Policies [Abstract] |
|
| SCHEDULE OF FAIR VALUE MEASURED ON RECURRING BASIS |
Assets
or liabilities measured at fair value or a recurring basis included embedded conversion options in convertible debt (see Note 6) and
were as follows on December 31, 2022 and September 30, 2022:
SCHEDULE
OF FAIR VALUE MEASURED ON RECURRING BASIS
| | |
December
31, 2022 | | |
September
30, 2022 | |
| Description | |
Level
1 | | |
Level
2 | | |
Level
3 | | |
Level
1 | | |
Level
2 | | |
Level
3 | |
| Derivative
liabilities | |
$ | — | | |
$ | — | | |
$ | 42,466,252 | | |
$ | — | | |
$ | — | | |
$ | — | |
|
| SCHEDULE OF VALUATION ON DERIVATIVE INSTRUMENTS |
A
roll forward of the level 3 valuation financial instruments is as follows:
SCHEDULE
OF VALUATION ON DERIVATIVE INSTRUMENTS
| | |
| | | |
| | |
| | |
For
the Three Months Ended December
31, | |
| | |
2022 | | |
2021 | |
| Balance
at beginning of period | |
$ | - | | |
$ | - | |
| Initial
valuation of derivative liabilities included in debt discount | |
| 16,069,178 | | |
| - | |
| Initial
valuation of derivative liabilities included in derivative expense | |
| 25,891,917 | | |
| - | |
| Change
in fair value included in derivative expense | |
| 505,158 | | |
| - | |
| Balance
at end of period | |
$ | 42,466,252 | | |
$ | - | |
|
| SCHEDULE OF CONTRACT LIABILITIES |
For
the three months ended December 31, 2022 and 2021, contract liabilities activity is as follows:
SCHEDULE OF CONTRACT LIABILITIES
| | |
December
31, 2022 | | |
December
31, 2021 | |
| Contract
liabilities beginning balance | |
$ | 156,550 | | |
$ | 135,150 | |
| Billings
and cash receipts on uncompleted contracts | |
| 24,000 | | |
| 43,000 | |
| Less:
revenues recognized during the period | |
| (3,500 | ) | |
| (22,250 | ) |
| Total
contract liabilities | |
$ | 177,050 | | |
$ | 155,900 | |
|
| SCHEDULE OF ANTI-DILUTIVE SHARES OUTSTANDING |
SCHEDULE OF ANTI-DILUTIVE SHARES OUTSTANDING
| | |
| | | |
| | |
| | |
December
31, | |
| | |
2022 | | |
2021 | |
| Stock
warrants | |
| 6,862,673,594 | | |
| 1,075,563,017 | |
| Stock
options | |
| 1,901,410,519 | | |
| - | |
| Series
C-1 preferred stock | |
| 212,431 | | |
| 445,301,289 | |
| Series
C-2 preferred stock | |
| - | | |
| 733,542,619 | |
| Series
E preferred stock | |
| - | | |
| 638,977,636 | |
| Series
F preferred stock | |
| - | | |
| 319,488,818 | |
| Convertible
notes | |
| 8,765,180,181 | | |
| 780,807,641 | |
| Total
antidilutive securities excluded from computation of earnings | |
| 17,529,476,725 | | |
| 3,993,681,020 | |
|